EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
08:30 – 09:30
WORKSHOPS AND ISPOR CHAPTER FORUMS – SESSION III (7 Concurrent)
Economic Outcomes Research
08:30 – 09:30
W13: OPENING THE BLACK BOX: INFORMING MODEL CHOICE FOR HEALTH TECHNOLOGY ASSESSMENT IN CANCER TREATMENT Discussion Leaders: Andrew Briggs DPhil, Professor, Public Health & Health Policy, University of Glasgow, Glasgow, UK; Mark Sculpher PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Neil S Hawkins PhD, Director, Oxford Outcomes (UK), Oxford, UK; Alison Griffiths Mph, Health Economist, Oxford Outcomes, Oxford, UK
08:30 – 09:30
W14: TRANSMISSION MODELING FOR ECONOMIC ASSESSMENTS OF VACCINES Discussion Leaders: Julie Roïz MSc, Senior Analyst, i3 Innovus, Uxbridge, UK; Sibilia Quilici MSc, Health Economic Manager, Sanofi Pasteur MSD, Lyon, France; Samuel Aballéa MSc, Senior Lead Analyst, i3 Innovus, Nanterre, France
Health Care Policy Development Using Outcomes Research
W16: ASSESSING PATIENT ADHERENCE FOR A POSITIVE CHANGE IN HEALTH BEHAVIOUR Discussion Leaders: Carla Dias Barbosa MSc, Research Manager, Mapi Values France, Lyon, France; Linda Abetz MA, Director - PRO, Mapi Values, Bollington, UK; Francois-Emery Cotte PharmD, MPH, Health Outcomes Researcher, Health Outcomes Studies, GlaxoSmithKline France, Marly le Roi, France; Benoit Arnould PhD, Director, France, Mapi Values, Lyon, France
08:30 – 09:30
W17: ELECTRONIC CAPTURE OF PROS - EPROS – STATUS TODAY AND TOMORROW? Discussion Leaders: Tara Symonds PhD, Senior Director, Outcomes Research, Global Market Access, Pfizer Ltd, Sandwich, Kent, UK; Ingela Wiklund PhD, Senior Research Leader, Center for Health Outcomes Research, United BioSource Corporation, London, UK; Alastair Glendenning PhD, Health Economics and Outcomes Research, Novartis Pharma, Horsham, West Sussex, UK; Lucy Abraham MSc, CPsychol, Associate Director, Outcomes Research, Pfizer Ltd, Sandwich, Kent, UK
Use of Real World Data
08:30 – 09:30
W18: USING SIMULATION TO BOOST EPIDEMIOLOGICAL STUDIES: IT SAVES THE DAY Discussion Leaders: Georgia Mitsi PhD, MBA, MSc, Manager, United BioSource Corporation, Lexington, MA, USA; Bernd Bruggenjurgen MD, MPH, Head, Alpha Care, Celle, Germany; J. Jaime Caro MDCM, FRCPC, FAC, Senior Vice President Health Economics, Heatlh Care Analytics, United BioSource Corporation, Lexington, MA, USA
08:30 – 09:30
FORUM SESSION III
GENERICS AND BIOANALOGS: NEW CHALLENGES
Room 341
Presented by the ISPOR Russia Regional Chapter
The forum will address the problems and prospects associated with the emergence of a large number of biological analogues of expensive drugs in drug treatment in Russia. The discussion will analyze public policies for generic substitution, the role of independent research for therapeutic equivalence and registers of patients in managing treatment of generics.
Speakers: Pavel Vorobiev MD, PhD, Professor, Head, Department of Hematology and Geriatrics, Moscow Medical Academy, Moscow, Russia and President, ISPOR Russia Regional Chapter; Oleg Borisenko MD, Executive Director, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
09:30 – 10:00
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
IP7: OUR MONEY OR YOUR RISK? RISK SHARING REIMBURSEMENT AGREEMENTS: IS THIS THE FUTURE? Moderator: Monique Martin MSc, MBA, Vice-President UK Operations, i3 Innovus, Uxbridge, Middlesex, UK Panelists: Michael F Drummond DPhil, Professor of Health Economics, University of York, Centre for Health Economics, York, UK; Alistair McGuire PhD, Chair in Health Economics, LSE Health and Social Care, London, UK
10:00 – 11:00
IP8: IQWIG AND THE EFFICIENCY FRONTIER – HOW CAN WE MEASURE PATIENT RELEVANT OUTCOMES? Moderator: F. Reed Johnson PhD, Principal Economist, RTI International, Research Triangle Park, NC, USA Panelists: Axel C. Mühlbacher PhD, MSc, Professor, Hochschule Neubrandenburg, IGM Institut of Health Economics and Health Care Management, Neubrandenburg, Germany; Olaf Pirk PhD, MD, Principal, Health Economics & Outcomes Research, IMS Health, Nuremberg, Germany; John FP Bridges PhD, Assistant Professor, Bloomberg School of Public Health, Health Policy and Management, Johns Hopkins University, Baltimore, MD, USA
10:00 – 11:00
IP9: HOW SHOULD HTA METHODS BE ADAPTED TO MEET THE RISING EXPECTATIONS OF DECISION MAKERS FOR MEDICAL DEVICES AND DIAGNOSTICS REIMBURSEMENT? Moderator: Annie M J Chicoye PhD, Expert, Pricing & Market Access Consulting, IMS Health France, Puteaux, France.
Panelists: Olivier Goeau-Brissoniere MD, Professor, Chairman, Federation des Specialités Medicales, Paris, France; Geoffroy Wilson MD, Reimbursement Leader EMEA, Emea, GE Healthcare, Chalfont St Giles , Buckinghamshire, UK; Adrian Griffin MSc, VP Strategic Affairs, LifeScan EMEA, Johnson & Johnson, High Wycombe, Buckinghamshire, UK
10:00 – 11:00
IP10: ESTIMATING THE COST-EFFECTIVENESS OF VACCINES – IS THE HEALTH ECONOMIST'S STANDARD TOOLBOX SUFFICIENTLY EQUIPPED? Moderator: Stuart Michael Carroll BA, (Hons), MSc, Research Associate and Policy Analyst, Centre for Health Economics and Policy, United BioSource Corporation, London, UK Panelists: Philippe Beutels BSc, MSc, PhD, Professor, Centre for Health Economics Research & Modeling Infectious Diseases (CHERMID), Centre for the Evaluation of Vaccination (CEV), University of Antwerp, Antwerp, Belgium; John Hutton PhD, Professor of Health Economics, Department of Health Sciences - Health Economics, University of York, York , UK; Carole Omnès PharmD, MSc, Health Economics Service Manager, Senior Market Access and Health Economics, Europe, Sanofi Pasteur MSD, Lyon, France
11:00 – 12:00
POSTER AUTHOR DISCUSSION HOUR – SESSION III
11:30 – 13:00
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
11:45 – 12:45
EDUCATIONAL SYMPOSIUM - Sponsored by European Federation of Pharmaceutical Industries and Associations (EFPIA)
Regulatory Review and Health Technology Assessment (HTA) - Opportunities and Limitations of an Integrative Approach
Involving Patients/Citizens in Health Care Decisions
The patient’s perspective is becoming more important in health care policy decisions worldwide. For example, in the UK, the NICE Citizens’ Council provides valuable input on a number of contentious subjects. An example of a recent report from the UK’s NICE Citizens’ Council on the issue: “Should NICE and its advisory bodies take into account the severity of a disease when making decisions? If yes, should the advisory committees: take severity into consideration alongside the cost and clinical effectiveness evidence; or should severity be included in the calculation of the QALY?”. The NICE Citizens’ Council report on this issue is attached: NICE Citizens Council Report on QALYs & Severity of Illness. In addition, patients, themselves, are becoming more proactive through patient advocacy groups, (e.g. European Patients' Forum) who collectively lobby for patients rights, including equity and access to health care technology in Europe. During this plenary session, a) how views of the general public are incorporated into health care coverage decisions, b) how information from “citizens’ councils” are incorporated into the decision process, and c) the role of patient advocacy groups in health care policy decisions will be presented and debated.
13:00 – 13:05
Moderator:
Ulf Persson PhD
Research Director, The Institute for Health Economics, Lund, Sweden
13:05 – 13:25
Patient, Carer and Public Involvement In NICE Decision-Making
Victoria Thomas MSc, Associate Director, Patient and Public Involvement, National Institute for Health and Clinical Excellence (NICE), London, UK Drawing on NICE’s extensive experience of involving patients and the public in its work, this session will explore the influence of lay people on NICE’s decision-making, the distinction between the view of patients and those of “the public”, and will use NICE’s Citizens Council as an illustration of meaningful lay engagement.
13:25 – 13:45
Role of Patient Advocacy Groups in Health Care Policy Decisions
Nicola Bedlington, Executive Director, European Patients’ Forum, Brussels, Belgium Drawing on the experience of the European Patients’ Forum, and some strong examples at EU level, this presentation will explore the rationale behind patient involvement in healthcare policy making, and some of the challenges in ensuring this involvement in meaningful.
13:45 – 14:00
Involving Citizens in Health Care Decisions in Sweden
Ulf Persson PhD, Research Director, The Institute for Health Economics, Lund, Sweden
14:00 – 14:15
DISCUSSION
14:15 – 14:30
ISPOR RESEARCH EXCELLENCE AND RESEARCH PRESENTATION AWARDS
14:30 – 14:45
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
14:45 – 15:45
WORKSHOPS AND ISPOR CHAPTER FORUMS – SESSION IV (7 Concurrent)
Economic Outcomes Research
14:45 – 15:45
W19: MODELING SLOWLY PROGRESSING CHRONIC DISEASES WITH EXACERBATIONS AND THEIR TREATMENTS: CHALLENGES IN MODELING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) Discussion Leaders: Maureen Rutten-van Molken PhD, Associate Professor, Health Economics, Institute for Medical Technology Assessment, Erasmus University and Erasmus MC, Rotterdam, The Netherlands; Talitha Feenstra PhD, Senior Health Economist RIVM and Assistant Professor HTA, Department of Epidemiology, RIVM and Department of Prevention and Health Services Research, University Medical Center Groningen, Bilthoven, The Netherlands; Sixten Borg MSc, Senior Project Manager, The Swedish Institute for Health Economics (IHE), Lund, Sweden
Health Care Policy Development Using Outcomes Research
14:45 – 15:45
W21: NEW HEALTH CARE SERVICES – THE PATHWAY INTO THE GERMAN SICK FUND MARKET Discussion Leaders: Olaf Pirk PhD, MD, Principal, Health Economics & Outcomes Research, IMS Health, Nuremberg, Germany; Axel C. Mühlbacher PhD, MSc, Professor, IGM Institut of Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany; Frank-Ulrich Fricke PhD, Principal, IMS Health, Nuremberg, Germany
W23: THE EMERGING ROLE OF OBSERVATIONAL DATA IN EVALUATING PRODUCT VALUE AND PRODUCT SAFETY Discussion Leaders: Jerome Wilson PhD, Senior Scientific Affairs Director, PRA, Rockville, MD, USA; Thomas F Goss PharmD, Vice President, Boston Healthcare Associates, Inc., Washington, DC, USA; Mark R Vanelli MD, MHS, MBA, Chief Medical Officer, Adheris Inc, Burlington, MA, USA
14:45 – 15:45
W24: POST-REIMBURSEMENT STUDIES ASSESSING GOOD MEDICATION USE IN REAL PRACTICE: FRENCH SITUATION Discussion Leaders: Emmanuelle Préaud PharmD, MSc, Research Manager, Health Outcomes and Market Access, Mapi Values France, Lyon, France; Juliette Longin PhD, Msc, Associate Director, Scientic Expertise and Proposal Development, Registrat-Mapi, Lyon, France; Stéphanie Tcherny MD, MSc, Responsable Recherche en pharmacoéconomie et pharmacoépidémiologie, Unité Pharmacoépidémiologie - Département médical, Lilly France, Suresnes, France; Marie-Christine Woronoff-Lemsi PharmD, PhD,
Professor,Hospital Pharmacist Doctor, CHU de Besançon, Jean Minjoz Hospital, Besançon, France
14:45 – 15:45
FORUM SESSION IV
QUALITY OF LIFE AND KNOWLEDGE ABOUT TOBACCO SMOKING TOXICITY AMONG SMOKERS OR SMOKERS WITH CHRONIC OBSTRUCTIVE LUNG DISEASES IN POLAND AND GREECE
Room 341
Presented by the ISPOR Poland and Greece Regional Chapters
Patient-reported outcomes (PRO) (e.g. global impression, functional status, HRQoL, symptoms) is still an evolving field in Poland and Greece. Nevertheless, it should be stressed that HRQOL is one of the more important endpoints in clinical and economic analysis, especially if cost-utility analysis is considered. Numerous topics will be discussed on this issue from the perspective of the experiences in Poland and Greece.
Moderators: Mary Geitona PhD, President, Hellenic Society of Pharmacoeconomics & Outcomes Research (HELSPOR), Assistant Professor, Department of Economics, University of Thessaly, Athens, Greece; Joanna Lis PhD, Health Economics Manager, Sanofi- Synthelabo, Warsaw, Poland
Speakers: Karina Jahnz-Rozyk MD, PhD, President, ISPOR Poland Regional Chapter, Head of Department of Immunology & Allergology, Military Institute of Health Service, Warsaw, Poland; John Yfantopoulos PhD, Professor of Health Economics, University of Athens and President of the National Centre for Social Research, Athens, Greece
15:45 – 16:00
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
16:00 – 17:00
WORKSHOPS – SESSION V (7 Concurrent)
Economic Outcomes Research
W25: USING EARLY ECONOMIC MODELLING TO INFORM STRATEGIC PRICING AND CLINICAL STUDY DESIGN Discussion Leaders: Adam C Lloyd MPhil, Senior Principal, Health Economics and Outcomes Research, IMS Health, London, UK; Michael Chambers MSc, Director of Health Economics, Global Health Outcomes, GlaxoSmithKline, Uxbridge, UK; Joe Caputo BSc, Engagement Manager, Health Economics and Outcomes Research, IMS Health, London, UK
W26: PRAGMATIC SELECTION OF APPROPRIATE MODELLING APPROACH IN PHARMACOECONOMIC EVALUATION Discussion Leaders: Sandrine Cure MSc, Project Leader, i3 Innovus, Uxbridge, Middlesex, UK; Lee Moore MSc, Health Economist, Roche Products Limited, Welwyn Garden City, Hertfordshire, UK; David Thompson PhD, Vice President, Global Health Economics, i3 Innovus, Medford, MA, USA
Health Care Policy Development Using Outcomes Research
W28: RECENT PROGRESS ON BEST-WORST SCALING: HEALTH-RELATED APPLICATIONS Discussion Leaders: Terry N Flynn PhD, Senior Research Fellow, Centre for the Study of Choice (CenSoC), University of Technology Sydney, Sydney, NSW, Australia; Jordan J Louviere PhD, Professor, Centre for the Study of Choice (CenSoC), University of Technology Sydney, Sydney, NSW, Australia; Emma McIntosh PhD, Senior Research Officer, Health Economics Research Centre, University of Oxford, Oxford, Oxfordshire, UK
